Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,714,269 shares of the biopharmaceutical company’s stock after selling 84,824 shares during the period. Bristol-Myers Squibb comprises 1.4% of Douglas Lane & Associates LLC’s holdings, making the stock its 17th largest position. Douglas Lane & Associates LLC owned approximately 0.08% of Bristol-Myers Squibb worth $96,959,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of BMY. Lantz Financial LLC boosted its holdings in Bristol-Myers Squibb by 17.4% in the 2nd quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 1,747 shares during the last quarter. Caprock Group LLC raised its stake in Bristol-Myers Squibb by 56.0% in the 2nd quarter. Caprock Group LLC now owns 44,767 shares of the biopharmaceutical company’s stock valued at $1,859,000 after purchasing an additional 16,069 shares during the last quarter. Quest Partners LLC lifted its holdings in Bristol-Myers Squibb by 29,957.4% in the 2nd quarter. Quest Partners LLC now owns 40,878 shares of the biopharmaceutical company’s stock valued at $1,698,000 after purchasing an additional 40,742 shares in the last quarter. First Foundation Advisors grew its holdings in shares of Bristol-Myers Squibb by 73.0% during the second quarter. First Foundation Advisors now owns 5,656 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 2,386 shares in the last quarter. Finally, Wedbush Securities Inc. raised its position in shares of Bristol-Myers Squibb by 2.4% in the second quarter. Wedbush Securities Inc. now owns 60,114 shares of the biopharmaceutical company’s stock valued at $2,497,000 after buying an additional 1,424 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Samit Hirawat acquired 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The stock was bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $55.00 to $73.00 in a research note on Tuesday, November 12th. Truist Financial upped their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Barclays lifted their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday, October 7th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $56.27.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded down $0.58 during trading hours on Wednesday, hitting $56.56. The company had a trading volume of 6,108,878 shares, compared to its average volume of 8,962,421. The business has a 50 day moving average of $57.31 and a 200-day moving average of $51.26. The company has a market cap of $114.71 billion, a PE ratio of -15.75, a price-to-earnings-growth ratio of 15.20 and a beta of 0.45. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.00 earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.38%. The ex-dividend date is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -69.08%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.